Logo image of RXST

RXSIGHT INC (RXST) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:RXST - US78349D1072 - Common Stock

11.27 USD
+0.6 (+5.62%)
Last: 11/26/2025, 3:01:40 PM
Fundamental Rating

3

Overall RXST gets a fundamental rating of 3 out of 10. We evaluated RXST against 188 industry peers in the Health Care Equipment & Supplies industry. RXST scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, RXST is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

RXST had negative earnings in the past year.
RXST had a negative operating cash flow in the past year.
RXST had negative earnings in 4 of the past 5 years.
In the past 5 years RXST always reported negative operating cash flow.
RXST Yearly Net Income VS EBIT VS OCF VS FCFRXST Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

RXST has a Return On Assets (-11.58%) which is comparable to the rest of the industry.
RXST has a better Return On Equity (-12.95%) than 64.89% of its industry peers.
Industry RankSector Rank
ROA -11.58%
ROE -12.95%
ROIC N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
RXST Yearly ROA, ROE, ROICRXST Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

Looking at the Gross Margin, with a value of 74.98%, RXST belongs to the top of the industry, outperforming 86.70% of the companies in the same industry.
In the last couple of years the Gross Margin of RXST has grown nicely.
RXST does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 74.98%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
RXST Yearly Profit, Operating, Gross MarginsRXST Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 1K -1K -2K

More info and screens

6

2. Health

2.1 Basic Checks

RXST does not have a ROIC to compare to the WACC, probably because it is not profitable.
RXST has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, RXST has more shares outstanding
Compared to 1 year ago, RXST has an improved debt to assets ratio.
RXST Yearly Shares OutstandingRXST Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
RXST Yearly Total Debt VS Total AssetsRXST Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

An Altman-Z score of 6.08 indicates that RXST is not in any danger for bankruptcy at the moment.
The Altman-Z score of RXST (6.08) is better than 79.26% of its industry peers.
A Debt/Equity ratio of 0.00 indicates that RXST is not too dependend on debt financing.
RXST has a Debt to Equity ratio of 0.00. This is in the better half of the industry: RXST outperforms 75.53% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.08
ROIC/WACCN/A
WACC8.68%
RXST Yearly LT Debt VS Equity VS FCFRXST Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

RXST has a Current Ratio of 12.74. This indicates that RXST is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 12.74, RXST belongs to the best of the industry, outperforming 97.34% of the companies in the same industry.
A Quick Ratio of 11.44 indicates that RXST has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 11.44, RXST belongs to the top of the industry, outperforming 95.74% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.74
Quick Ratio 11.44
RXST Yearly Current Assets VS Current LiabilitesRXST Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The earnings per share for RXST have decreased by -6.02% in the last year.
Looking at the last year, RXST shows a quite strong growth in Revenue. The Revenue has grown by 10.75% in the last year.
RXST shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 128.63% yearly.
EPS 1Y (TTM)-6.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
Revenue 1Y (TTM)10.75%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-14.09%

3.2 Future

RXST is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.61% yearly.
The Revenue is expected to grow by 2.50% on average over the next years.
EPS Next Y-74.25%
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%
EPS Next 5Y6.61%
Revenue Next Year-10.36%
Revenue Next 2Y-2.2%
Revenue Next 3Y2.02%
Revenue Next 5Y2.5%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
RXST Yearly Revenue VS EstimatesRXST Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 50M 100M 150M
RXST Yearly EPS VS EstimatesRXST Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

RXST reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RXST is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RXST Price Earnings VS Forward Price EarningsRXST Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RXST Per share dataRXST EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

RXST's earnings are expected to decrease with -14.72% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RXST!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RXSIGHT INC

NASDAQ:RXST (11/26/2025, 3:01:40 PM)

11.27

+0.6 (+5.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-05 2025-11-05/amc
Earnings (Next)02-26 2026-02-26/amc
Inst Owners96.45%
Inst Owner Change-11.08%
Ins Owners5.56%
Ins Owner Change10.37%
Market Cap461.17M
Revenue(TTM)142.09M
Net Income(TTM)-35.73M
Analysts52.5
Price Target9.86 (-12.51%)
Short Float %10.01%
Short Ratio5.05
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)10.6%
Min EPS beat(2)-16.68%
Max EPS beat(2)37.88%
EPS beat(4)3
Avg EPS beat(4)10.37%
Min EPS beat(4)-16.68%
Max EPS beat(4)37.88%
EPS beat(8)7
Avg EPS beat(8)18.14%
EPS beat(12)11
Avg EPS beat(12)20.21%
EPS beat(16)15
Avg EPS beat(16)18.27%
Revenue beat(2)1
Avg Revenue beat(2)5.69%
Min Revenue beat(2)-6.3%
Max Revenue beat(2)17.67%
Revenue beat(4)1
Avg Revenue beat(4)1.66%
Min Revenue beat(4)-6.3%
Max Revenue beat(4)17.67%
Revenue beat(8)4
Avg Revenue beat(8)2.11%
Revenue beat(12)8
Avg Revenue beat(12)3.07%
Revenue beat(16)12
Avg Revenue beat(16)5.11%
PT rev (1m)7.41%
PT rev (3m)7.41%
EPS NQ rev (1m)7.58%
EPS NQ rev (3m)7.58%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)-3.6%
Revenue NQ rev (3m)-3.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.25
P/FCF N/A
P/OCF N/A
P/B 1.67
P/tB 1.67
EV/EBITDA N/A
EPS(TTM)-0.88
EYN/A
EPS(NY)-1.19
Fwd EYN/A
FCF(TTM)-0.54
FCFYN/A
OCF(TTM)-0.46
OCFYN/A
SpS3.47
BVpS6.74
TBVpS6.74
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -11.58%
ROE -12.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 74.98%
FCFM N/A
ROA(3y)-26.56%
ROA(5y)-20.32%
ROE(3y)-38.11%
ROE(5y)-28.71%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y52.32%
GM growth 5YN/A
F-Score5
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 120.49%
Cap/Sales 2.49%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.74
Quick Ratio 11.44
Altman-Z 6.08
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)107.67%
Cap/Depr(5y)87%
Cap/Sales(3y)4.72%
Cap/Sales(5y)8.01%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-50%
EPS Next Y-74.25%
EPS Next 2Y-28.33%
EPS Next 3Y-14.72%
EPS Next 5Y6.61%
Revenue 1Y (TTM)10.75%
Revenue growth 3Y83.65%
Revenue growth 5Y128.63%
Sales Q2Q%-14.09%
Revenue Next Year-10.36%
Revenue Next 2Y-2.2%
Revenue Next 3Y2.02%
Revenue Next 5Y2.5%
EBIT growth 1Y-16.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-27.97%
EBIT Next 3Y5.73%
EBIT Next 5YN/A
FCF growth 1Y56.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y60.43%
OCF growth 3YN/A
OCF growth 5YN/A

RXSIGHT INC / RXST FAQ

What is the ChartMill fundamental rating of RXSIGHT INC (RXST) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RXST.


Can you provide the valuation status for RXSIGHT INC?

ChartMill assigns a valuation rating of 0 / 10 to RXSIGHT INC (RXST). This can be considered as Overvalued.


What is the profitability of RXST stock?

RXSIGHT INC (RXST) has a profitability rating of 2 / 10.


Can you provide the financial health for RXST stock?

The financial health rating of RXSIGHT INC (RXST) is 6 / 10.